Original article

Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study

Asako Doi^{a,b,*}, Kentaro Iwata^c, Hirokazu Kuroda^{a,b}, Toshikazu Hasuie^{a,b}, Seiko Nasu^{a,d}, Aya Kanda^d, Tomomi Nagao^d, Hiroaki Nishioka^b, Keisuke Tomii^e, Takeshi Morimoto^f, Yasuki Kihara^g

^a Department of Infection Control, Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan

^b Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan

^c Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, Chuoku, 6500017, Kobe, Hyogo, Japan

^d Department of Laboratory Medicine, Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan

^e Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan

^f Department of Clinical Epidemiology, Hyogo Medical College, Mukogawa, 6638501, Nishinomiya, Hyogo, Japan

^g Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan

ARTICLE INFO

Keywords:

Coronavirus disease 2019 (COVID-19)

SARS-CoV-2

Seroprevalence

ABSTRACT

Objectives: Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively smaller number of its infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.

Methods: We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex.

Results: There were 33 positive IgG among 1000 serum samples (3.3%, 95%CI: 2.3–4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934–69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8–3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333–59,221). These numbers were 396 to 858-fold more than confirmed cases with PCR testing in Kobe City.

Conclusions: Our cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.

1. Introduction

Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively small number of infections as well as deaths among developed nations. A total of 92,373 patients were diagnosed as COVID-19 with 1675 deaths as of October 20, 2020.¹ In Kobe City, which is located in the middle of Japan, 1125 patients were identified with 15 deaths as of October 20, 2020.² However, with restricted use of polymerase chain reaction (PCR) testing to diagnose COVID-19 in

Japan, some might be skeptical about the figure, with potential many undiagnosed people without PCR testing, especially at early stage of the epidemic in Japan.³ Accurate prevalence of COVID-19 in Japan remains unknown and many are concerned about this uncertainty. To estimate actual number of infected persons in community, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.

* Corresponding author. Department of Infectious Diseases, Kobe City Medical Center General Hospital, Chuoku, 6500047, Kobe, Hyogo, Japan.

E-mail address: asakodoi@gmail.com (A. Doi).

<https://doi.org/10.1016/j.cegh.2021.100747>

Received 1 November 2020; Accepted 12 April 2021

Available online 19 April 2021

2213-3984/© 2021 The Authors. Published by Elsevier B.V. on behalf of INDIACLEN. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

2. Methods

We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody (immunoglobulin G, or IgG) at Kobe City Medical Center General Hospital, a tertiary care medical center in Kobe, Japan. Tests were done for randomly selected preserved serum from patients who visited outpatient clinics of the hospital and received blood testing for any reason. Patients who visited the emergency department or the designated fever consultation service with symptoms associated with COVID-19 were excluded to avoid the overestimation of SARS-CoV-2 infection. The serums of patients who visited the center from March 31 to April 7 were used for the analysis. Serums were preserved at -20°C and were defrosted upon testing. An immunochromatographic test to detect IgG against SARS-CoV-2 was used for the analysis (RC-NC002, KURABO Industries Ltd. <https://www.kurabo.co.jp/bio/English/index.html>). We did not perform immunoglobulin M (IgM) testing since our aim was not to find currently infected persons. Ten microliter of serum was infused into the test kit, and the interpretation of the test results were made 15 min after the buffer was placed. Tests were conducted for 1000 samples, stratified by the decade of age and sex, with 50 samples taken from each stratum. If there were less than 50 samples from any stratum, additional samples were randomly obtained from other strata until all 1000 samples were completed. The tests were performed with interpretation of the results by 3 laboratory technicians (SN, AK, TN) and 2 infectious diseases specialists (AD and KI). This study was conducted anonymously with exception of age groups and sex to make any sample become anonymous so that the individual identification of sample was completely impossible. Informed consent from patients was exempted due to anonymity of the current study. The estimate of this study was prevalence of seropositivity of IgG and its 95% confidence interval (CI). Both unadjusted and age and sex adjusted estimations of number of seropositive persons in Kobe city were also calculated. For unadjusted estimation, we used Kobe City website for population of Kobe City (of April 1, 2020 <https://www.city.kobe.lg.jp/a89138/shise/toke/toukei/jinkou/index.html>). For age and sex adjusted estimation, we used data of national census conducted in 2015 (<https://www.city.kobe.lg.jp/a89138/shise/toke/toukei/kokutyou/tyoubutsujinkou.html>). The number of confirmed cases as of April 7, 2020 was 69 and used based on the data presented by Kobe City (https://www.city.kobe.lg.jp/a57337/kenko/health/coronagaiyo1_100.html).

The ethics committee at Kobe City Medical Center General Hospital approved the current study.

3. Results

There were 33 positive IgG among 1000 serum samples (3.3%, 95% CI: 2.3%–4.6%). By applying the estimate to census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934–69,868). Since total number of infected patients reported at Kobe City as of April 7 were only 69, these estimates were 506 to 1013-fold more than confirmed cases then.

Table 1
Sample characteristics.

Ages	Male	Test positive	Female	Test positive
Under 10-year-old	7	0	1	0
10–19	17	0	10	0
20–29	17	0	19	0
30–39	41	1	49	2
40–49	64	2	91	3
50–59	84	4	80	2
60–69	87	2	84	3
70–79	85	6	81	3
80–89	81	1	83	4
Over 90	6	0	13	0
Total	489	16	511	17

Sample characteristics are shown on Table 1 stratified by the decade of age and sex of the patients. Table 2 shows age and sex distribution of Kobe City at the national census held in 2015. The age and sex adjusted percentage of positivity was 2.7% (95%CI: 1.8–3.9%). Using calculated population of Kobe City in national census of 2015 (1,518,478), estimated number of people with positive IgG was 40,999 (95%CI: 27,333–59,221). These numbers were 396 to 858-fold more than confirmed cases in Kobe City.

4. Discussion

Our cross-sectional serological survey identified far more patients than those actually diagnosed by PCR testing. The prime minister of Japan Shinzo Abe declared the state of emergency in the afternoon on April 7, 2020, and it means that samples of our analysis reflect the status before the state of emergency.⁴

Japan's government tried to restrict the number of PCR testing to avoid a collapse of health care system in Japan, and only those who with persisting symptoms or those with risk factors were allowed to take PCR. It was considered that identifying clusters occurring in Japan with monitoring and isolating close contacts with the identified patients were prudent strategy and it would be able to comprehend the trend of COVID-19 infections in Japan.⁵ However, since difference between those who were identified and those who actually had infections was so huge according to our findings, Japan might not have comprehended the epidemic dynamics occurring in the nation.

The thought that confirmed COVID-19 cases were a tip of iceberg is not new. A similar study by Bendavid et al. identified that seroprevalence of SARS-CoV-2 at Santa Clara County, the United States, was 1.5%, and the estimated number of cases were 50–85-fold more than confirmed cases.⁶ A previous study tried to estimate actual cases of COVID-19 and it concluded that close to half the cases are identified in Japan.⁷ We consider this report underestimated the actual infection rate and excessively overestimated the ability of Japan's capability of diagnosing COVID-19. The study on the outbreak of COVID-19 in a cruise ship Diamond Princess suggested that there are about 20–40% asymptomatic cases among those infected with SARS-CoV-2,⁸ and this could suggest finding of every case of COVID-19 rather unrealistic. However, even with this assumption, missing most cases than identified by PCR-testing might not be acceptable, and better strategy should have been implemented to better fight against this infection.

Because of the low number of confirmed cases in Japan, there was discussion whether Japan is different from other nations in terms of transmissibility of SARS-CoV-2. Our analysis suggests that the transmissibility of the virus in Japan might not differ significantly from other countries. This means the difference in behavior of Japanese people, such as lack of hugs or kissing in public, custom of taking off shoes at the entrance, or wearing of masks for protection purpose before the outbreak, might not be the reason. Rather, Japan probably had

Table 2
Population of Kobe City based on 2015 census. Total number of the populations are aggregates of all age groups, which are different from what the census figure showed.

Ages	Male (%)	Female (%)
Under 10-year-old	61,242 (8.6)	58,671 (7.3)
10–19	70,275 (9.8)	67,661 (8.4)
20–29	73,973 (10.3)	78,787 (9.8)
30–39	87,806 (12.3)	95,510 (11.9)
40–49	109,303 (15.3)	116,372 (14.5)
50–59	89,500 (12.5)	98,220 (12.2)
60–69	105,160 (14.7)	114,649 (14.3)
70–79	77,705 (10.9)	96,228 (12.0)
80–89	36,428 (5.1)	61,344 (7.6)
Over 90	4475 (0.6)	15,169 (1.9)
Total	715,867	802,611

significant transmission of SARS-CoV-2 like other countries. On the other hand, is the data on mortality due to COVID-19 reliable in Japan? There is no thorough investigation on the accuracy of mortality data regarding COVID-19 in Japan, but concordance of death certificates and autopsy diagnoses for pneumonia in Japan was only 9%, and the possibility of underestimates of mortality also needs to be considered.⁹ If we consider the mortality data in Japan accurate, it raises another question why there is fewer deaths due to COVID-19 in Japan. Vaccination of BCG (Bacille de Calmette et Guérin) are hypothesized to affect the clinical impact of COVID-19,¹⁰ but further studies will be needed to confirm its effects.

Our study has several inherent limitations. First, the sensitivity and specificity of serology assay to estimate the prevalence of SARS-CoV-2 infection is not fully studied.¹¹ There might be underdiagnosis of the viral infection, particularly at the early stage of infection, or those with immunosuppressed. The possibility of overdiagnosis by cross-reaction with other viruses, such as conventional coronavirus as a cause of common cold should be considered.¹² For example, if the serology assay for seroprevalence had sensitivity and specificity of 90% and 99% respectively, adjusted Clopper-Pearson exact 95% confidence interval would be 1.5%–4%. With unknown sensitivity and specificity of current test kits as of this writing, further studies will be needed to investigate these to overcome this inherent problem. Second, the population of our cohort might not be the same as one in Kobe City. The samples were obtained from the patients from the clinic. Although we adjusted the age and sex distribution to fit the general population, the selection bias should be unavoidable. This is mainly due to the practicality of conducting the current study. Japan was under the state of emergency during the study, and the public health officials as well as health care personnel were too busy to deal with the pandemic, making the planning of random collection of the blood samples from the citizens impossible. Further serological studies targeting randomly selected people in Kobe City could clarify this potential limitation. However, even we put these potential limitations into consideration, the difference between what had been reported as the confirmed cases and estimated cases in our study is huge, and this suggests that there are far more infected persons in Kobe city than those detected by PCR testing. Our findings might be useful in revising the testing policy for diagnosing COVID-19 in future to more accurately estimate the number of infected in the city.

In conclusion, our cross-sectional serological study suggests that the actual number of people with SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing. Further studies are needed to elucidate the seroprevalence in other regions in Japan.

Declaration of competing interest, and funding statement

The study was conducted using unrestricted research funds of Division of Infectious Diseases Therapeutics, Kobe University Graduate School of Medicine, provided by Tsumura & Co. and Takasago Seibu Hospital. The authors all declare no competing interests.

Ethical approval

This study was approved by the ethics committee at Kobe City Medical Center General Hospital.

Acknowledgements

We thank Ms. Toko Nakata and Mako Miyawaki for aiding the purchase of test kits.

References

- 1 Saito T. *The Secret of Japan's Success in Combating COVID-19* [Internet]. The Japan Times; 2020 [cited 2020 October 20]. Available from <https://www.japantimes.co.jp/opinion/2020/06/02/commentary/japan-commentary/secret-japans-success-combating-covid-19/>.
- 2 Ministry of Health and Labor of Japan. Situation update on June 13, 2020, on coronavirus diseases. in Japanese. Viewed on https://www.mhlw.go.jp/stf/newpage_14241.html; 2019. Accessed October 20, 2020.
- 3 Omori R, Mizumoto K, Chowell G. Changes in testing rates could mask the novel coronavirus disease (COVID-19) growth rate. *Int J Infect Dis*. 2020;94:116–118.
- 4 Japan PM Abe Declares State of Emergency amid Widespread Virus Infections [Internet]. Kyodo News+; 2020 Oct 20. Available from <https://english.kyodonews.net/news/2020/04/ac4415709921-abe-to-declare-state-of-emergency-amid-widespread-virus-infections.html>.
- 5 Nishiura H, Oshitani H, Kobayashi T, et al. Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). *medRxiv*. 2020 Mar 3, 2020.02.28.20029272.
- 6 Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody seroprevalence in Santa Clara county, California. *medRxiv*. 2020 Apr 17, 2020.04.14.20062463.
- 7 Omori R, Mizumoto K, Nishiura H. Ascertainment rate of novel coronavirus disease (COVID-19) in Japan. *medRxiv*. 2020 Mar 10, 2020.03.09.20033183.
- 8 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan. *Euro Surveill*. 2020;25:2000180, 2020.
- 9 Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. *J Epidemiol*. 2016;26:191–198.
- 10 Akiyama Y, Ishida T. Relationship between COVID-19 death toll doubling time and national BCG vaccination policy. *medRxiv*. 2020 Apr 23, 2020.04.06.20055251.
- 11 Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for certainty on covid-19 antibody tests — at what cost? *N Engl J Med*. 2020 Jun 5, 0(0):null.
- 12 Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581:465–469.